2015 Lasker-DeBakey Clinical Medical Research Award. You can also search for this author in
Ann Oncol 2017;28:iv119-42.76. Ann Oncol. Little CC. The cost of the typical treatment using antibodies to ICIs is near $150,000 a year.
Kaiser J. Personalized tumor vaccines keep cancer in check. Cancer immunotherapies, which were developed based on studies of the mechanisms of tumor escape, manipulate the immune system to reactivate the antitumor immune response and overcome the pathways leading to escape.
Leal AD, Paludo J, Finnes HD, Grothey A. Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition.
Keywords: Small cell lung cancer , targeted therapy , immunotherapy , adverse events , predicative biomarkers , repurposing drug
CTLA‐4 is expressed on the surface of CD4‐positive and CD8‐positive lymphocytes and competes with the T‐cell–costimulatory receptor CD28 for binding to T‐cell–costimulatory factors, which are expressed on the surface of antigen‐presenting cells in the early phase of the immune response.ICIs bind to immune checkpoint proteins to overcome this tumor‐mediated inhibition of T‐cell function.Disinhibition of T‐cell function by ICIs can lead to a spectrum of inflammatory side effects, or irAEs. Oral Oncol 2015;51:221-8.75.
Porter RR. Mar 11, 2020.
Gay P, Prasad V. Few people actually benefit from "breakthrough" cancer immunotherapy.
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion.
Immune cell promotion of metastasis.
Am J Clin Oncol 2016;39:98-106.68.
However, many investigational strategies look beyond checkpoint blockade. Nature 1987;328:267-70.62. The hydrolysis of rabbit y-globulin and antibodies with crystalline papain.
Primary, adaptive, and acquired resistance to cancer immunotherapy.
Identification of a novel cell type in peripheral lymphoid organs of mice. Ann Oncol.
Science 1991;254:1643-7.37. The Scientist 2017; April 1.
Bacteria as tumor therapeutics?
1. 2018;379(22):2108–21.Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, De Castro JG, et al.
N Engl J Med. FDA News Release.
2018;36(15_suppl):9003.Verzoni E, Carteni G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, et al. Assays of PD-L1 protein expression by immunohistochemistry are used to determine which tumors would best be treated with an anti-PD-L1 antibody, but it is an imperfect measurement practice because there is lack of standardization of methods and it can sometimes be difficult to differentiate PD-L1-positive tumor cells from the other PD-L1-positive cells in the tumor microenvironmentAnti-PD-1 and anti-PD-L1 antibody treatments are currently the most investigated ICIs because they have shown less severe toxicity, or high-grade “immune-related adverse effects” (irAEs), than anti-CTLA-4 antibody treatments (5-20% compared to 10-40% respectively)These drugs have powerful effects, as seen when a Phase I trial using an antibody to the CD28 ligand nearly cost the lives of all six healthy volunteers in a British study when a cytokine storm was provoked, associated with multiorgan failure and resuscitation in the intensive care unitThe less toxic antibodies to checkpoint inhibitors have shown a great deal of promise and are now approved by the FDA for six malignancies which are in advanced stages - melanoma, lung cancer, renal cell carcinoma, head and neck cancer, urothelial cancer, and Hodgkin’s lymphoma - with many other tumor types being investigated in clinical trialsThe immunotherapy/immuno-oncology field has shown such exponential gains in recent times, associated with an accumulation of a dizzying array of complex results arriving from numerous clinical trials, that mechanistic patient studies are necessary to best advance understanding. Burnet FM. Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, Reid TR. Prediction of CAR T-related toxicities in R/R DLBCL patients treated with Axicabtagene Ciloleucel using point of care cytokine measurements.
Regarding the regional distribution of registered clinical immunotherapy trials a shift from PD-1 / PD-L1 trials (mainly performed in the US and Europe) to CAR T cell trials (majority of trials performed in the US and China) can be noted.The importance of immunotherapy has been acknowledged by the This review focuses on clinical and pre-clinical findings that might guide future clinical application of CPIs in general.